NASDAQ · FMS
Healthcare · Medical - Care Facilities
$22.07
Up+$0.13 (+0.59%)
Updated Sep 18, 2026, 11:08 PM
SID Score
5.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
FMS closed at $22.07 after 20 trading sessions, down 5.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $22.67 | $22.68 | $22.05 | $22.07 | 1.25M |
| Sep 16, 2026 | $22.94 | $23.10 | $22.86 | $22.97 | 363.86K |
| Sep 15, 2026 | $22.89 | $23.005 | $22.77 | $22.96 | 446.18K |
| Sep 14, 2026 | $22.77 | $22.895 | $22.67 | $22.86 | 646.82K |
| Sep 11, 2026 | $22.49 | $22.54 | $22.25 | $22.35 | 584.83K |
| Sep 10, 2026 | $22.39 | $22.41 | $22.2059 | $22.23 | 459.89K |
| Sep 9, 2026 | $22.34 | $22.37 | $22.215 | $22.33 | 366.46K |
| Sep 8, 2026 | $22.76 | $22.78 | $22.44 | $22.45 | 804.78K |
| Sep 4, 2026 | $22.66 | $22.78 | $22.56 | $22.66 | 480.31K |
| Sep 3, 2026 | $22.80 | $22.83 | $22.28 | $22.47 | 648.59K |
| Sep 2, 2026 | $22.58 | $22.86 | $22.58 | $22.65 | 646.53K |
| Sep 1, 2026 | $22.98 | $23.0162 | $22.705 | $22.74 | 778.98K |
| Aug 31, 2026 | $22.91 | $22.91 | $22.70 | $22.74 | 601.23K |
| Aug 28, 2026 | $23.16 | $23.24 | $22.91 | $23.10 | 715.63K |
| Aug 27, 2026 | $23.19 | $23.37 | $23.08 | $23.27 | 534.27K |
| Aug 26, 2026 | $23.65 | $23.66 | $23.40 | $23.40 | 877.37K |
| Aug 25, 2026 | $23.39 | $23.51 | $23.31 | $23.51 | 622.77K |
| Aug 24, 2026 | $23.46 | $23.58 | $23.39 | $23.53 | 510.82K |
| Aug 21, 2026 | $23.42 | $23.565 | $23.375 | $23.43 | 826.63K |
| Aug 20, 2026 | $23.68 | $23.915 | $23.295 | $23.43 | 787.07K |
The latest Smart Investors Daily articles mentioning FMS.
FMS research
Company profile and research snapshot.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 30, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
| Jun 18, 2026 | METZLER EQUITIES | Buy | — |
| Jun 17, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
| May 20, 2026 | TRUIST SECURITIES | Hold | — |
| May 14, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 7, 2026
The U.S. Food and Drug Administration (FDA) on Tuesday issued a warning letter to Fresenius Medical Care AG & Co. KGaA’s Fresenius USA Manufacturing following a March 2026 inspection at its Ogden, Utah production facility. In a letter to the...
Benzinga · Sep 4, 2026
FDA warns Fresenius over Utah plant violations, citing leaking dialysis bags and visual inspection failures. Read the full compliance update.
Yahoo · Sep 3, 2026
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
Yahoo · Sep 3, 2026
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FMS.
